Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR

The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.

Inclusion Criteria:

• Clinical diagnosis of acromegaly
• The patient must have been tested at Week -4 (4 weeks prior to the Baseline visit) and shown to have a GH level <10 mU/L.
• The patient must have been treated with a stable dose of octreotide LAR for at least four months prior to study entry
• Life expectancy of at least 2 years

Exclusion Criteria:

• Adenectomy within past 6 months, or likely during study period
• Radiotherapy for acromegalic disease within 1 year, or likely during study period
• Unstable concomitant dopamine agonist therapy